The Motley Fool

2 UK dividend stocks I’d add to my portfolio today

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

Private investor buying UK shares at home
Image source: Getty Images

Stock investments such as funds or individual shares can be roughly categorised into two types – growth and income. Investors can make strategic decisions about whether they want to keep their profits as income, or reinvest them to achieve more growth.

One of the most popular ways income investors try to generate a regular amount of money every month is by buying dividend stocks.

5 Stocks For Trying To Build Wealth After 50

Markets around the world are reeling from the coronavirus pandemic… and with so many great companies trading at what look to be ‘discount-bin’ prices, now could be the time for savvy investors to snap up some potential bargains.

But whether you’re a newbie investor or a seasoned pro, deciding which stocks to add to your shopping list can be a daunting prospect during such unprecedented times.

Fortunately, The Motley Fool UK analyst team have short-listed five companies that they believe STILL boast significant long-term growth prospects despite the global upheaval…

We’re sharing the names in a special FREE investing report that you can download today. And if you’re 50 or over, we believe these stocks could be a great fit for any well-diversified portfolio.

Click here to claim your free copy now!

Rather than making regular payouts to investors in the form of dividends, some companies choose to use the same capital to make further investments to contribute to the growth of the company and its share price.

While there is no right or wrong investment strategy to pursue, I like to look at dividend stocks that can supplement my regular income. Here are two FTSE 100 stocks I would buy for their strong dividend yields today.

National Grid

Many companies have either stalled or cut their dividend payouts since the start of the pandemic last year. Utilities company National Grid (LSE:NG.) was one of the few that was able to keep increasing its dividend due to the defensive nature of its business.

The company owns the electricity infrastructure that operates throughout all of England and Wales. This makes it a key component in the energy sector in the UK.

Based on National Grid’s current share price of 860p, the company’s dividend yield stands at 5.6%. That’s higher than the 4.8% average of all FTSE 100 constituents.

I see National Grid’s dividend yield as being one of the steadiest in the index, with management keen to continue growing its dividend whenever possible.

There is a risk to investing in National Grid, however. The share price growth has not been spectacular by any means.

The shares have been flat over the last six months. Over the last year, they have decreased in value by 17%. NG shares will need to see growth to make that attractive dividend yield work hard for investors.

Another risk to the investment is increasing scrutiny from energy regulator Ofgem. Most recently, Ofgem called for National Grid to be stripped of its role managing the UK’s electricity transmission network.

This regulatory action poses a constant threat to the National Grid share price. But for me the outlook is positive enough as a dividend investment if the payout growth continues.


Pharmaceutical giant GlaxoSmithKline (LSE:GSK) has seen its share price suffer as competitors Pfizer and AstraZeneca saw their Covid-19 vaccines approved towards the end of 2020. GSK says its own vaccine will be ready by the end of 2021, in collaboration with French drug giant Sanofi.

The share price has fallen 23% in the last year. It also slumped earlier this month as the company forecast earnings per share to decline in 2021.

However, I feel there is an opportunity to buy GSK shares today. While it may not have been the first pharma company to roll out a Covid-19 vaccine, demand for new jabs amid the emergence of new variants means the eventual arrival of GSK’s vaccine will be more than welcome.

With a dividend yield of 6.5%, the shares seem cheap to me as an income investment. The last year has shown how vital pharma companies are and I think that will continue to be the case for a long time.

Is this little-known company the next ‘Monster’ IPO?

Right now, this ‘screaming BUY’ stock is trading at a steep discount from its IPO price, but it looks like the sky is the limit in the years ahead.

Because this North American company is the clear leader in its field which is estimated to be worth US$261 BILLION by 2025.

The Motley Fool UK analyst team has just published a comprehensive report that shows you exactly why we believe it has so much upside potential.

But I warn you, you’ll need to act quickly, given how fast this ‘Monster IPO’ is already moving.

Click here to see how you can get a copy of this report for yourself today

conorcoyle has no position in any of the shares mentioned. The Motley Fool UK has recommended GlaxoSmithKline. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

Our 6 'Best Buys Now' Shares

Renowned stock-picker Mark Rogers and his analyst team at The Motley Fool UK have named 6 shares that they believe UK investors should consider buying NOW.

So if you’re looking for more stock ideas to try and best position your portfolio today, then it might be a good day for you. Because we're offering a full 33% off your first year of membership to our flagship share-tipping service, backed by our 'no quibbles' 30-day subscription fee refund guarantee.

Simply click below to discover how you can take advantage of this.